Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

GRIFOLS BUYS CONTROL OF COMPETING PLASMA MANUFACTURER

Grifols SA, a Spanish chemical and pharmaceutical giant, will buy a controlling stake in Germany’s Biotest AG for €1.6 billion, the companies announced.
Like Grifols, Biotest manufactures blood plasma products.
Grifols will pay €43 a share to acquire Biotest shares owned by Tiancheng International Investment, based in Hong Kong, which would give Grifols 89.88 percent of Biotest’s ordinary shares that carry voting rights, Reuters reported.
Tiancheng is a division of Creat Group, which has sought to unload its Biotest investment after U.S. regulators balked at the company’s expansion in the U.S., which makes up about half the world’s blood plasma market.
The regulators demanded that Creat sell Biotest’s U.S. operations before Creat would be allowed to engage in other business in the country.
Creat also is far along in discussions to sell Bio Products Laboratory, its British blood plasma subsidiary.
Together, the two sales will largely reverse the international acquisitions in the blood plasma business that Creat began in 2016.
In contrast, Grifols has been expanding through acquisitions in Asia and the U.S.
TRENDPOST: We enjoy being accurate in our forecasts, but do not always enjoy what those forecasts mean.
“Bigs getting bigger” is a long-term trend we not only forecast years ago (for example, in “Brick-and-Mortar Bounce,” 7 Dec 2017), but also foresee continuing indefinitely.
Too few politicians are concerned about this concentration of social and economic power to act, especially when Bigs lard office-holders’ re-election funds with legal bribery known as “donations.”
Change will only come about when the public acts, either by electing reform crusaders to public office or by taking to the streets to protest Bigs’ power if and when an organizing force for that movement emerges.